The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / PsA Trial Design Can Improve Patient Safety, Outcomes

PsA Trial Design Can Improve Patient Safety, Outcomes

June 15, 2022 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF

2022 ACR-FDA SUMMIT—With numerous effective treatments now available for psoriatic arthritis (PsA), trials in this disease should look for deeper states of remission and avoid placebo-only arms, said Laura Coates, MD, PhD, consultant rheumatologist and NIHR clinician scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, U.K.

You Might Also Like
  • How to Leverage Patient-Reported Outcomes to Improve Care for SLE Patients
  • Risankizumab May Improve Symptoms of PsA
  • The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice
Also By This Author
  • A New Frailty Index Aids Lupus Assessment

Dr. Coates

Dr. Coates and co-presenter Alexis Ogdie, MD, MSCE, associate professor of medicine and epidemiology and director of the Penn Psoriatic Arthritis and Spondyloarthritis Program, Hospital of the University of Pennsylvania, Philadelphia, addressed PsA outcomes in clinical trials during the 2022 ACR-FDA Summit held virtually in May.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Inflammation, impact of disease and damage to joints/functional impairments are three areas to measure when assessing PsA, Dr. Coates said. Ultimately, the areas that are measured should be what matter most to patients, she added. Research from 2017 found that outcomes related to pain, fatigue, physical fitness and the reduction of joint damage were the most important to patients with PsA.1

Another consideration is the use of single measures (e.g., dactylitis, nail disease) vs. composite measures, Dr. Coates said. Single measures may be the primary outcome for studies focused on single domains; composite measures allow a better estimation of full disease activity and may influence the treatment decision given overall disease burden.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

For composite measures, many trials use the ACR20, ACR50 and ACR70 response criteria. Some studies still use the Disease Activity Score-28 (DAS-28), which Dr. Coates described as problematic because it does not provide an accurate disease measure for PsA.

Alexis R. Ogdie-Beatty, MD, MSCE

Dr. Ogdie

Among the composite measures for PsA, Drs. Coates and Ogdie view the Minimal Disease Activity Score (MDA) as more accurate for psoriatic disease and more relevant for clinical practice. In February, the European Medicines Agency issued a letter of support for the MDA as a primary outcome measure for PsA.2

Aim High

Aiming for stricter remission criteria should be another priority for better patient outcomes, Dr. Ogdie said. She shared a patient example: A chef developed inflammatory arthritis, particularly in her hands. This ended her career. She started with 15 swollen joints and 18 tender joints. Under the ACR20 criteria, she would still have 12 swollen joints and 14 tender joints, as well as enthesitis and dactylitis. “The patient is not well [with this],” Dr. Ogdie said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Using ACR50 or ACR70 criteria, her joint count reduces—even enough that she could theoretically return to work. However, these outcome measures cannot be directly applied to clinical practice. Other measures, such as MDA and the Disease Activity in Psoriatic Arthritis (DAPSA) score, can be applied in practice and are more meaningful.

Pages: 1 2 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: ACR-FDA Summit, clinical trials, Psoriatic Arthritis, study design

You Might Also Like:
  • How to Leverage Patient-Reported Outcomes to Improve Care for SLE Patients
  • Risankizumab May Improve Symptoms of PsA
  • The Big Picture: How to Assess Disease Activity in Patients with axSpA & PsA in Clinical Practice
  • Will an App to Monitor Patient Outcomes Improve RA Disease Activity?

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)